|
5.5 ASCO
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
5.5.1.2 ASCO (général) - Académiques
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.5.12 ASCO (médico-éco)
|
|
|
|
|
Big returns on small cancer research investment, study suggests [Reuters]
|
|
|
|
|
|
For
the 23 successful trials, researchers calculated how many cancer
patients might survive for a year who might otherwise have died without
the new therapies developed through the SWOG effort. By dividing those
years of life saved by the estimated cost of all SWOG studies since
1956, Unger and his colleagues calculated that it took a National Cancer
Institute investment of only $125 for each year of life saved.
|
|
|
|
|
|
|
5.5.13 ASCO (divers)
|
|
|
|
|
How a simple tech tool can help cancer patients live longer [Washington Post]
|
|
|
|
|
|
Lead
study author Ethan Basch, an oncologist at Lineberger Comprehensive
Cancer Center at the University of North Carolina at Chapel Hill,
acknowledges that a five-month improvement might sound modest. But, he
notes, it is a greater benefit than what's provided by many targeted
drugs for metastatic cancer.
|
|
|
|
|
|
|
5.5.13.1 ASCO (divers-radiothérapie)
|
|
|
|
|
5.5.13.2 ASCO (divers-psy)
|
|
|
|
|
|
|
5.5.15 ASCO (biopsies liquides)
|
|
|
New Technology Dives Deep Into the Cancer Genome [ASCO]
|
|
|
|
|
|
This
approach, however, differs from liquid biopsies, including commercial
tests, which only profile a relatively small portion of the genome in
patients already diagnosed with cancer for the purpose of helping
monitor the disease or detect actionable alterations that can be matched
to available drugs or clinical trials.
|
|
|
|
|
|
|
|
|
5.5.16 ASCO (médecine de précision)
|
|
|
|
|
5.5.16.1 ASCO (médecine de précision-TRK)
|
|
|
|
|
|
|
|
|
5.5.18 ASCO (observation)
|
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
|
|
Roche Takes Another Cancer-Drug Hit [Bloomberg]
|
|
|
|
|
|
Roche
Holding AG has been a dominant cancer-drug maker for years, meaning the
annual meeting of the American Society for Clinical Oncology (ASCO) is
usually a showcase for it. Not this time.
|
|
|
|
|
|
|
|
|
|
Triumph in Breast Cancer: KuDOS to Lynparza [OBR]
|
|
|
|
|
|
The
discussant, Dr. Allison Kurian, had an overall positive outlook stating
that these results” are practice-changing.” However, the magnitude of
the benefit (3 months difference) and lack of OS benefit could raise
questions by others in the field about the clinical meaningfulness of
these results.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
|
|
|
|
|
|
|
|
|
5.5.4 ASCO (immunothérapies)
|
|
|
|
|
|
|
|
Kite to launch mid-stage leukemia trial in fourth quarter 2017 [Reuters]
|
|
|
|
|
|
Axi-cel
belongs to a new class of therapies called chimeric antigen receptor
T-cells (CAR-T) using a complicated process of extracting immune system T
cells from an individual patient, altering their DNA to sharpen their
ability to spot and kill cancer cells, and infusing them back into the
patient.
|
|
|
|
|
|
|
|
5.5.4.1 ASCO (immunothérapies-IDO)
|
|
|
|
|
|
|
5.5.5 ASCO (gastro-intestinal)
|
|
|
|
|
|
5.5.6 ASCO (peau-mélanome)
|
|
|
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
|
|
|
|
5.5.9 ASCO (autres organes)
|
|
|
|